Study:
A Multicenter, Open-Label, Phase III, Randomized, Active-Controlled Trial Evaluating The Efficacy, Safety, And Pharmacokinetics Of rhuMAb VEGF (BEVACIZUMAB), In Combination With Capecitabine Chemotherapy, In Subjects With Previously Treated Metastatic Breast Cancer
Rationale:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them
or deliver tumor-killing substances to them without harming normal cells. It is not yet known
if chemotherapy is more effective with or without monoclonal antibody in treating metastatic
breast cancer.
Purpose:
Randomized phase III trial to study the effectiveness of capecitabine with or
without bevacizumab in treating women who have metastatic breast cancer.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Breast Cancer |
Drug: bevacizumab
Drug: capecitabine |
Phase 3 |
Verified by
Genentech
September, 2005
Sponsored by: Genentech
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00012285
Study Type: Interventional
Study Design: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Amy Vassel, MD., Study Chair